Compare COSM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | LEXX |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.9M |
| IPO Year | 2013 | N/A |
| Metric | COSM | LEXX |
|---|---|---|
| Price | $0.38 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 934.4K | 173.0K |
| Earning Date | 11-17-2025 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,792,819.00 | $522,000.00 |
| Revenue This Year | $20.69 | $13.35 |
| Revenue Next Year | $53.10 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.69 | 5.05 |
| 52 Week Low | $0.28 | $0.46 |
| 52 Week High | $1.32 | $1.90 |
| Indicator | COSM | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 37.10 |
| Support Level | $0.35 | $0.67 |
| Resistance Level | $0.47 | $0.79 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.72 | 4.85 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.